Table 1. Replication of vaccine virus and clinical assessment in adults, RSV-seropositive children, and RSV-seronegative children.

NT, not tested.

Viral detection
(culture)
Viral detection
(qPCR)
% with indicated illness*
SubjectsDose
(log10
PFU/ml)
No. of
subjects
%
Infected
% Shedding
virus
Peak titer mean
(SD) log10
PFU/ml
Peak copy
number log10
(SD)
FeverURILRICoughOMRespiratory
or febrile
illness
Other
Adults
  Vaccinees6.015000.6 (0.0)NT0200702027
Seropositive children
  Vaccinees6.0101000.6 (0.0)NT0400004020
  Placebo
recipients
Placebo52000.6 (0.0)NT00000060
Seronegative children
  Vaccinees5.02095851.5 (0.9)3.4 (0.9)208503558545
  Infected
placebo
recipient
Placebo11001002.0 (0.0)3.3 (0.0)1001000001000
  Placebo
recipients
Placebo9000.6 (0.0)1.7 (0.0)224403306778

*Illness abbreviations and definitions are as described in the text. URI was defined as rhinorrhea, pharyngitis, or hoarseness, and LRI was defined as wheezing, rhonchi, or rales, or having been diagnosed with pneumonia or laryngotracheobronchitis (croup).

†% Shedding vaccine virus as detected by culture and/or rRT-qPCR. The limit of detection of vaccine virus was 0.6 log10 PFU/ml by culture, and 1.7 log10 copy numbers/ml by rRT-qPCR.

‡Data from the seronegative placebo recipient, as described in the text.